Previous 10 | Next 10 |
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Und...
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the latest results of the fall 2023 drilling campaign, on the Crevier niobium & tantalum project (the “Crevier Proje...
MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce that, in accordance with the requirements of the TSX Venture Exchange and further to its news release dated February 7, 2024 (e...
MONTREAL, Feb. 07, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the execution of a definitive option agreement (the “Option Agreement”, the “Option”), with Vior In...
2024-01-30 09:26:33 ET More on NovaBay NovaBay Pharmaceuticals, Inc. (NBY) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on NovaBay Historical earnings data for NovaBay Financial information for NovaBay Read the full article o...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova ® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com. A substantial ...
MONTRÉAL, Jan. 18, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to provide an update on its recent activities, including its application for authorization to add three years to the James Bay Niobium...
EMERYVILLE, CA and BOULDER, CO / ACCESSWIRE / January 9, 2024 / NovaBay Pharmaceuticals, Inc. (NYSE American:NBY) and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova ® -branded products by Sonoma in the European Union. The new pr...
MONTRÉAL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- NioBay Metals inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the first results of the Fall 2023 drilling program at its 72.5%-owned Crevier niobium & tantalum project (the “...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes. A free webinar is being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific time, and eyecare professionals ca...
News, Short Squeeze, Breakout and More Instantly...
NovaBay Pharmaceuticals Inc. Company Name:
NBY Stock Symbol:
NYSE Market:
NovaBay Pharmaceuticals Inc. Website:
Net product sales increased 13% over the prior year driven by higher sales of Avenova ® -branded products through OTC channels and branded wound care products Sales and marketing expenses declined 15% reflecting continued digital marketing optimization Ordered product sal...
Ordered product sales of Avenova ® -branded products on Amazon.com set back-to-back records in March and April 2024 Enhanced marketing program provides potential for additional growth in the U.S. dry eye disease treatment market projected to reach nearly $5 billion by 2030 ...
MONTREAL, May 07, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is proud to announce that, following re-sampling of historic Vior drill holes from the Foothills Project, assay results confirm the presence of phospha...